The Food and Drug Administration recently gave its approval for Novavax’s updated protein-based Covid vaccine, allowing for emergency use in individuals aged 12 and over. This move opens up the competition in the market, pitting Novavax against the well-known Pfizer and Moderna vaccines this coming fall and winter.
Novavax’s vaccine is specifically designed to target the omicron subvariant JN.1, which has been rapidly spreading within the United States since the beginning of the year. Although JN.1 currently only represents a small fraction of all cases nationwide, Novavax believes that their vaccine can still provide protection against the dominant descendants of JN.1, such as KP.2.3, KP.3, KP.3.1.1, and LB.1.
Novavax has stated that they anticipate their vaccine to be widely available in numerous locations throughout the country, including retail pharmacies, independent pharmacies, and regional grocers. Following the FDA’s announcement, Novavax’s shares experienced an increase of over 8%, indicating positive market sentiment towards the company’s vaccine.
While Pfizer and Moderna utilize mRNA technology in their vaccines to trigger an immune response by instructing cells to produce proteins, Novavax takes a different approach with its protein-based technology, which has been used for years in vaccines against diseases like hepatitis B and shingles. This variety in vaccine technology offers individuals an alternative option if they are hesitant to take an mRNA vaccine.
As we head into the fall and winter months, the approval of Novavax’s Covid vaccine provides the population with more choices when it comes to protecting themselves against the virus. With the ongoing evolution of Covid variants, having a diverse range of vaccines available is crucial in ensuring widespread immunity and combatting the spread of the virus. The competition between Novavax, Pfizer, and Moderna will undoubtedly lead to advancements in vaccine technology and accessibility for individuals across the country.